Last updated:
30th December 2024
See answers to previous information requests
How to search
- Select a year and/or a month from the drop down list
- Type a subject into the 'Subject keyword(s):' search (Optional)
- Click 'Search' button
Alternatively click 'View' to browse through all received requests.
This search is for our information requests from September 2020 onward.
Long-acting injectable buprenorphine Buvidal
See notes
Follow on request from WBCIR:21503
1. What proportion of your total current OST caseload are patients currently receiving Buvidal treatment (regardless of when they were initiated)?
In other words, I'm looking for the total number of active Buvidal patients as a percentage of your total active OST caseload, not just the percentage represented by new initiations in a single year.
If your previous response provided the proportion for newly initiated patients only, could you please provide the proportion that all current Buvidal patients represent of your total OST caseload?
1.
a) Does your current contract with your drug and alcohol treatment provider(s) include provision for Buvidal (long-acting injectable buprenorphine)? Please provide a yes/no answer for each financial year.
2022/23: No
2023/24: No
2024/25: No
b) If yes, when was Buvidal first included as a funded treatment option within your commissioned services?
2022/23: N/A
2023/24: N/A
2024/25: N/A
c) Does your council have a written policy, clinical pathway, or formulary decision regarding Buvidal? If so, please provide a copy or summary.
2022/23: No
2023/24: No
2024/25: No
2.
a) What was the total expenditure on Buvidal within your commissioned drug and alcohol treatment services in each financial year?
2022/23: £0.00
2023/24: £16,455.97
2024/25: £23,715.53
b) From which budget line(s) was this expenditure drawn (e.g. Public Health Grant, SSMTRG, DATRIG, or other)?
2022/23: N/A
2023/24: Public Health Grant
2024/25: SSMTRG & public health grant
3.
a) How many patients were initiated on Buvidal in each financial year?
2022/23: 9
2023/24: 10
2024/25: 6
b) What proportion of your total opioid substitution therapy (OST) caseload does this represent?
2022/23: 3.86%
2023/24: 4.69%
2024/25: 2.67%
4.
a) Has your council or your commissioned provider(s) conducted any formal review or assessment of Buvidal as a treatment option? If so, please provide any written outputs from this review.
2022/23: No
2023/24: No
2024/25: No
b) Are there any documented reasons why Buvidal has not been commissioned or expanded, if applicable?
2022/23: Funding restrictions
2023/24: Funding restrictions
2024/25: Funding restrictions
